Vertex Pharmaceuticals

Joshua Boger, Ph.D., founded Vertex in 1989 with $6 million in venture capital and a dream to create a new kind of pharmaceutical company. After more than a decade at Merck, where he was told that most of the medicines he would work on would never make it to a patient, he left and founded Vertex with the idea that no challenge should ever be too great. From the very first day, Vertex has pushed the boundaries of what’s possible in medicine with the simple goal of improving the lives of people with serious diseases. Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies.
Company Growth (employees)
Type
Public
HQ
Boston, US
Founded
1989
Size (employees)
2,150 (est)+11%
Website
vrtx.com
Vertex Pharmaceuticals was founded in 1989 and is headquartered in Boston, US

Key People at Vertex Pharmaceuticals

Larry Bock

Larry Bock

Co-Founder
Ian F. Smith

Ian F. Smith

Executive Vice President & CFO
Stuart A. Arbuckle

Stuart A. Arbuckle

Executive Vice President and Chief Commercial Officer
Amit K. Sachdev

Amit K. Sachdev

Senior Vice President,Global Government Strategy, Market Access and Value

Vertex Pharmaceuticals Office Locations

Vertex Pharmaceuticals has an office in Boston
Boston, US (HQ)
50 Northern Ave

Vertex Pharmaceuticals Metrics

Vertex Pharmaceuticals Financial Metrics

Revenue (2016)

$1.7 b

Revenue growth (2015-16), %

65%

Net income (2016)

($84 m)

Market capitalization (21-Mar-2017)

$22.6 b

Closing share price (21-Mar-2017)

$91.3

Cash (31-Dec-2016)

$1.2 b
Vertex Pharmaceuticals's current market capitalization is $22.6 b.
Vertex Pharmaceuticals's revenue was reported to be $1.7 b in FY, 2016 which is a 64.9% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$1.2 b$580.4 m$1 b$1.7 b

Revenue growth, %

(52%)78%65%

Operating expense total

$2.1 b$1.3 b$1.5 b$1.7 b

EBIT

($903.4 m)($692.4 m)($466.9 m)$9.9 m

EBIT margin, %

(75%)(119%)(45%)1%

Interest expense

$22.7 m$72.9 m$84.2 m$81.4 m

Interest income

$22.7 m

Pre tax profit

($976.1 m)

Income tax expense

($288.6 m)$7 m$30.4 m$16.7 m

Net Income

($687.6 m)($742.7 m)($588.2 m)($84 m)
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$569.3 m$625.3 m$714.8 m$1.2 b

Accounts Receivable

$85.5 m$76 m$177.6 m$201.1 m

Inventories

$14.1 m$30.8 m$57.2 m$77.6 m

Current Assets

$1.6 b$1.5 b$1.4 b$1.8 b

PP&E

$696.9 m$715.8 m$697.7 m$698.4 m

Goodwill

$31 m$39.9 m$50.4 m$50.4 m

Total Assets

$2.3 b$2.3 b$2.5 b$2.9 b

Accounts Payable

$49.3 m$71.2 m$74.9 m$61.5 m

Current Liabilities

$397.8 m$368.3 m$506.3 m$792.5 m

Additional Paid-in Capital

$5.3 b$5.8 b$6.2 b$6.5 b

Retained Earnings

($4 b)($4.7 b)($5.3 b)($5.4 b)

Total Equity

$1.1 b$1.3 b

Financial Leverage

2.3 x2.2 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($687.6 m)($742.7 m)($588.2 m)($84 m)

Depreciation and Amortization

$48.4 m$63.3 m$62.3 m$61.4 m

Accounts Receivable

$53.4 m$7.4 m($100 m)($33 m)

Inventories

$7.1 m($16 m)($23 m)($16 m)

Accounts Payable

($49.2 m)$25 m($1.7 m)($11.7 m)

Cash From Operating Activities

($51.6 m)($513.2 m)($365.4 m)

Cash From Investing Activities

($54.1 m)$74 m$268.9 m$104.5 m

Interest Paid

$11 m$8.7 m$85.6 m$83.7 m

Income Taxes Paid

$2.8 m$1.2 m$1.8 m

Vertex Pharmaceuticals Market Value History

Vertex Pharmaceuticals Online Presence

Vertex Pharmaceuticals News

Vertex Pharmaceuticals Company Life

You may also be interested in